Form 4: NewAmsterdam Pharma CSO Sells $2.5M in Shares

NewAmsterdam Pharma's Chief Scientific Officer, Johannes Jacob Pieter Kastelein, reported planned sales of 100,000 ordinary shares totaling approximately $2.5 million.

Summary

• Johannes Jacob Pieter Kastelein, Chief Scientific Officer and Director of NewAmsterdam Pharma Co N.V., reported planned sales of 100,000 ordinary shares.
• The sales are scheduled to occur on August 21, 2025, and August 22, 2025.
• On August 21, 2025, 50,000 shares are planned to be sold at a weighted average price of $24.29 per share, with prices ranging from $23.73 to $24.57.
• On August 22, 2025, two transactions are planned: 42,342 shares at a weighted average price of $25.08 (ranging from $24.39 to $25.35) and 7,658 shares at a weighted average price of $25.49 (ranging from $25.39 to $25.62).
• These transactions are being conducted pursuant to a Rule 10b5-1(c) plan, indicating they are pre-arranged.
• Following these planned transactions, Kastelein's indirect beneficial ownership will be 69,302 ordinary shares.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant insider selling by a key executive, even though it's under a 10b5-1 plan. This type of transaction can still be perceived as a lack of strong conviction or a move to diversify, which might concern investors.

Positives

• The sales are conducted under a Rule 10b5-1(c) plan, which suggests the transactions are pre-scheduled and not based on new, non-public information.

Negatives

• Significant insider selling by a key executive (CSO and Director) could be perceived negatively by the market, potentially signaling a lack of confidence or a desire to diversify holdings.
• The total value of shares sold is approximately $2.48 million, representing a substantial divestment.

Future Outlook

The filing does not provide any forward-looking statements or guidance beyond the planned transaction dates.

Management Comments

• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

Industry Context

Insider selling by a Chief Scientific Officer in a pharmaceutical company can sometimes raise questions about the executive's long-term view of the company's pipeline or market position, although sales under a 10b5-1 plan are often for personal financial planning and diversification.

Related Party Transactions

• The ordinary shares are held by Futurum B.V. for the benefit of the Reporting Person, with the Reporting Person exercising sole voting and investment control.

Stakeholder Impact

• Shareholders may interpret the insider selling as a signal of reduced confidence, potentially leading to downward pressure on the stock price.
• Employees might observe the executive's divestment, though the 10b5-1 plan mitigates immediate concerns about company health.

Next Steps

• The planned sales of ordinary shares are scheduled for August 21, 2025, and August 22, 2025.

Key Dates

Recommendation

While significant insider selling by a key executive is generally a negative signal, the fact that these transactions are pre-planned under a Rule 10b5-1(c) plan mitigates the immediate concern that the sales are based on new, adverse non-public information. Investors should monitor future filings and company performance, but a 'hold' recommendation is appropriate given the pre-scheduled nature of the sales, which often relate to personal financial planning rather than a direct commentary on the company's immediate prospects.

Keywords

NewAmsterdam Pharma, NAMS, Insider Selling, Form 4, Johannes Jacob Pieter Kastelein, Chief Scientific Officer, Director, Equity Sales, 10b5-1 Plan